Table 1 Criteria for evaluation of response of breast lesions and axillary lymph nodes by DCE-MRI versus PET/CT
Response category | Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Eisenhauer et al. 2009) [23] | PET Response Criteria in Solid Tumors (PERCIST) (Wahl et al. 2009) [24] |
|---|---|---|
Complete response (CR) | Disappearance of all target lesions Reduction in short axis of target lymph nodes to < 10 mm | Disappearance of all lesions on PET images to background blood- pool levels, regardless of % change from baseline and anatomic size |
Partial response (PR) | ≥ 30% decrease in sum of target lesion diameter sum | ≥ 30% decrease in sum of target lesion SUV |
Progressive disease (PD) | ≥ 20% increase in sum of target lesion diameter and minimum of 5 mm total increase or new lesion | 30% increase in sum of target lesion SUV or new FDG avid lesion |
or unequivocal progression of non-target lesions | or unequivocal progression of non-target lesion (e.g., ≥ 30% increase) or unequivocal progression by RECIST | |
Stable disease (SD) | Does not meet other criteria | Does not meet other criteria |
Axillary lymph nodes assessment | Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node must be ≥ 15 mm in short axis. At baseline and in follow-up, only the short axis will be measured and followed | Follow the same criteria as the breast lesions regarding SUV change (CR, PR, PD and SD) |